Involvement of focal adhesion kinase in cellular proliferation, apoptosis and prognosis of laryngeal squamous cell carcinoma

Li, D W; Sun, Yajing; Sun, Zhenfeng; Dong, Pin

doi:10.1017/s0022215112001971

Cited by 4 publications

(2 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mean percentage of patients with advanced stages of disease was 52.0% (range, 0–100%). Five studies evaluated hepatocellular carcinoma [ 34 , 35 , 39 , 46 , 56 ], Four studies each evaluated gastric cancer [ 10 , 33 , 37 , 47 ] and ovarian cancer [ 36 , 41 , 49 , 58 ], three studies each evaluated lung cancer [ 40 , 45 , 55 ], and colorectal cancer[ 52 – 54 ], two studies each evaluated pancreatic cancer [ 15 , 44 ], and cholangiocarcinoma [ 38 , 42 ], and one study each evaluated breast cancer [ 48 ], gliomas [ 49 ], endometrial carcinoma [ 32 ], esophageal squamous cell carcinoma [ 16 ], renal cancer [ 51 ], tongue squamous cell carcinoma [ 50 ], and laryngeal squamous cell carcinoma [ 57 ]. Twenty studies were performed in Asian populations, while the remaining 10 studies were conducted in Western populations.…”

Section: Resultsmentioning

confidence: 99%

Prognostic Value of Focal Adhesion Kinase (FAK) in Human Solid Carcinomas: A Meta-Analysis

Zeng

et al. 2016

PLoS ONE

View full text Add to dashboard Cite

BackgroundRecently, the number of reports on focal adhesion kinase (FAK) as a vital therapeutic target in solid carcinomas has increased; however, the prognostic role of FAK status remains poorly understood. This study aims to evaluate the prognostic effect of FAK by means of a meta-analysis.MethodsWe performed a systematic literature search in order to examine the correlation between expression of FAK and overall survival(OS). The hazard ratio (HR) of OS was used to measure survival. A random-effects model was used to pool study statistics. Sensitivity and publication bias analyses were also conducted.ResultsThirty eligible studies involving 4702 patients were included. The median expression rate of FAK was 54%. Meta-analysis of the HRs demonstrated that high FAK expression was associated with worse OS (average HR = 2.073, 95%confidence interval[CI]:1.712–2.510, p = 0.000). Regarding cancer type, FAK was associated with worse OS in gastric cancer (HR = 2.646,95% CI:1.743–4.017, p = 0.000), hepatocellular carcinoma (HR = 1.788,95% CI:1.228–2.602, p = 0.002), ovarian cancer (HR = 1.815, 95% CI: 1.193–2.762, p = 0.005), endometrial cancer (HR = 4.149, 95% CI:2.832–6.079, p = 0.000), gliomas (HR = 2.650, 95% CI: 1.205–5.829, p = 0.015), and squamous cell carcinoma (HR = 1,696, 95% CI: 1.030–2.793, p = 0.038). No association was found between HR and disease staging according to our meta-regression analysis.ConclusionsOur study shows that high expression of FAK is associated with a worse OS in patients with carcinomas, but the association between FAK and prognosis varies according to cancer type. The value of FAK status in clinical prognosis in cancer needs further research.

show abstract

Section: Resultsmentioning

confidence: 99%

Prognostic Value of Focal Adhesion Kinase (FAK) in Human Solid Carcinomas: A Meta-Analysis

Zeng

et al. 2016

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Li et al demonstrated that Akt promotes cell survival through its ability to phosphorylate and activate several pro-apoptotic targets. Subsequent consequences of this include the phosphorylation of Fak and the activation of signal transduction pathways, ultimately contributing to AURKA-mediated tumorigenesis (31). However, the pathway by which the migration and invasion of HNSCC was enhanced was not determined.…”

Section: Discussionmentioning

confidence: 99%

AURKA promotes cell migration and invasion of head and neck squamous cell carcinoma through regulation of the AURKA/Akt/FAK signaling pathway

Yang

Shan

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

Abstract. The present study aimed to investigate the mechanism by which Aurora kinase A (AURKA) promotes cell migration and invasion in head and neck squamous cell carcinoma (HNSCC). Transwell assays were performed to investigate the cell migration and invasion abilities of AURKA, whilst western blotting was used to analyze the protein expression in FaDu and Hep2 cells, each treated with pharmacological inhibitors. Following the inhibition of AURKA, Akt and focal adhesion kinase (FAK), the migration and invasion of the FaDu and Hep2 cells decreased. The expression of phosphorylated (p)-AURKA and p-FAK (Y397) was observed to decrease following FaDu and Hep2 cell treatment with VX-680, a small molecular inhibitor of AURKA. The expression of p-Akt and p-FAK (Y397) ceased following treatment with the Akt inhibitor triciribine. The expression of p-FAK (Y397) decreased, however, p-Akt expression did not change following treatment with the FAK inhibitor TAE226. In conclusion, AURKA activates FAK through the AURKA/Akt/FAK signaling pathway, promoting the migration and invasion of HNSCC cells, which may subsequently provide a novel approach for the treatment of HNSCC.

show abstract

Aberrant expressed long non-coding RNAs in laryngeal squamous-cell carcinoma

Wang

et al. 2019

American Journal of Otolaryngology

View full text Add to dashboard Cite

Involvement of focal adhesion kinase in cellular proliferation, apoptosis and prognosis of laryngeal squamous cell carcinoma

Abstract: These findings suggest that focal adhesion kinase may affect laryngeal squamous cell carcinoma progression through regulation of cell apoptosis and proliferation. Focal adhesion kinase expression is a major prognostic factor in laryngeal cancer patients.

Cited by 4 publications

References 21 publications

Prognostic Value of Focal Adhesion Kinase (FAK) in Human Solid Carcinomas: A Meta-Analysis

Prognostic Value of Focal Adhesion Kinase (FAK) in Human Solid Carcinomas: A Meta-Analysis

AURKA promotes cell migration and invasion of head and neck squamous cell carcinoma through regulation of the AURKA/Akt/FAK signaling pathway

Aberrant expressed long non-coding RNAs in laryngeal squamous-cell carcinoma

Contact Info

Product

Resources

About